Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics

Corcept Therapeutics Incorporated (CORT)

Today's Latest Price: $28.60 USD

0.08 (0.28%)

Updated Jan 27 3:33pm

Add CORT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 485 in Biotech

See all "A" rated Strong Buy stocks

CORT Stock Summary

  • The ratio of debt to operating expenses for Corcept Therapeutics Inc is higher than it is for about merely 5.18% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for Corcept Therapeutics Inc; that's greater than it is for just 9.2% of US stocks.
  • With a year-over-year growth in debt of 293.64%, Corcept Therapeutics Inc's debt growth rate surpasses 94.64% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Corcept Therapeutics Inc are AMPH, FORM, LSCC, BMRN, and PXLW.
  • Visit CORT's SEC page to see the company's official filings. To visit the company's web site, go to

CORT Stock Price Chart Interactive Chart >

Price chart for CORT

CORT Price/Volume Stats

Current price $28.60 52-week high $29.87
Prev. close $28.52 52-week low $9.70
Day low $27.52 Volume 535,429
Day high $29.87 Avg. volume 539,859
50-day MA $25.27 Dividend yield N/A
200-day MA $18.14 Market Cap 3.32B

Corcept Therapeutics Incorporated (CORT) Company Bio

Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.

CORT Latest News Stream

Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream

Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about Corcept Therapeutics Inc that investors may wish to consider to help them evaluate CORT as an investment opportunity.

Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Yahoo | December 31, 2020

What Can We Make Of Corcept Therapeutics' (NASDAQ:CORT) CEO Compensation?

Joseph Belanoff became the CEO of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) in 1999, and we think it's a good...

Yahoo | December 21, 2020

Is CORT A Good Stock To Buy According To Hedge Funds?

In this article we will analyze whether Corcept Therapeutics Incorporated (NASDAQ:CORT) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Yahoo | December 19, 2020

Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 3, 2020

George Baker Is The Independent Director of Corcept Therapeutics Incorporated (NASDAQ:CORT) And Just Spent US$243k On Shares

Potential Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders may wish to note that the Independent Director...

Yahoo | November 13, 2020

Read More 'CORT' Stories Here

CORT Price Returns

1-mo 7.32%
3-mo 66.67%
6-mo 91.30%
1-year 112.80%
3-year 13.94%
5-year 683.56%
YTD 9.33%
2020 116.20%
2019 -9.43%
2018 -26.02%
2017 148.76%
2016 45.78%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9656 seconds.